Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?

Recently, the World Health Organization (WHO) released the updated guideline on the treatment for multi-drug resistant tuberculosis (MDR-TB) treatment regimens based on new experimental and observational evidence [1]. In this new guidance the most important drugs are the late-generation fluoroquinolones (i.e. levofloxacin and moxifloxacin), linezolid and bedaquiline. Despite the new guidance, MDR- and extensively drug resistant (XDR) TB treatment is challenging due to the risk of drug-related adverse events (AE) and drug–drug interactions (DDI). Precision medicine-based approach to minimise the risk of resistance emergence and amplification and to provide patients with the highest standard of care has been recommended [2].

Source: European Respiratory Journal - February 11, 2020 Category: Respiratory Medicine Authors: Alffenaar, J.-W. C., Akkerman, O. W., Tiberi, S., Sotgiu, G., Migliori, G. B., on behalf of the Global Tuberculosis Network Bedaquiline study group Tags: Original Articles: Research letters Source Type: research